E

    Elevai Labs, Inc. Common Stock (ELAB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $5.19
    -0.12 (-2.26%)

    Market Cap: $4.30M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    PeriodReportedEst.SurpriseB/MYoY
    Jun 26
    		$-0.61N/AN/ABeat+92.8%
    Mar 26
    		$-111.75N/AN/ABeat-3753.4%
    Dec 25
    		$-519.17N/AN/ABeat-447.4%
    Sep 25
    		$-4.95N/AN/ABeat+100.0%
    Jun 25
    		$-8.44$0.00N/AMiss+100.0%
    Mar 25
    		$-2.90N/AN/ABeat+100.0%
    Sep 24
    		$-94.85N/AN/ABeat-
    Jun 24
    		$-90777.00N/AN/ABeat-
    Mar 24
    		$-94818.36N/AN/ABeat-
    Dec 23
    		$-78576.99N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-0.00EV/EBITDAN/A
    Price/FCF-2.80xFCF Yield-35.72%
    Profitability
    Profit Margin0.00%Operating Margin-290.00%
    ROE-105.20%ROIC-31.01%
    Financial Health
    Debt/Equity0.54xInterest Coverage-7.77x
    Current Ratio1.36xQuick Ratio1.30x
    Trading Statistics
    Beta-0.25Avg Volume286.23K
    52-Week High$2671.2052-Week Low$5.24

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$6.13
    SMA 20$7.68
    SMA 50$9.64
    SMA 200$209.15
    EMA 10$6.26
    EMA 20$7.29
    EMA 50$12.11
    EMA 200$440.33

    MACD

    Line: -1.36Signal: -1.23Hist: -0.13

    ADX

    ADX: 33.8+DI: 5.6-DI: 2.0

    Aroon & PSAR

    Aroon Up76.0
    Aroon Down68.0
    PSAR$1.29

    Bollinger Bands

    Upper Band$11.14
    Lower Band$4.22
    %B Position9010%(Upper)
    Band Width0.14

    RSI (14-Day)

    Oversold
    27.2

    Momentum Oscillators

    Stoch %K74.2
    Stoch %D77.7
    Williams %R-29.7
    ROC (10d)-40.5%
    Momentum-3.54
    CCI (20d)53.2
    MFI (14d)36.0

    Volatility Measures

    ATR (14d)$5.49(105.9%)
    StdDev (20d)1.73
    Hist Vol143.3%(High)

    Volume Flow

    VWAP$5.21
    OBV445.6M
    AD Line1443.1B
    CMF (20d)156.089

    Volume Metrics

    Avg Vol (20d)289.7K
    Vol Ratio0.1x(Low)
    VWMA (20d)$7.16

    Pivot Points

    R3$6.50
    R2$6.24
    R1$5.77
    Pivot Point$5.51
    S1$5.04
    S2$4.78
    S3$4.31

    Advanced Oscillators

    TSI-40.75
    Ultimate Osc65.1
    KST-363.46

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$1.31M$681,994$18,188$571,896$0$0$-1,747,570$0$0$0$-1,014,004$554,654
    Cost of Revenue$920,919$453,087$-115,727$520,497$0$0$590,819$0$0$0$-341,122$188,509
    Gross Profit$385,691$230,474$107,284$78,030$0$0$-1,747,570$0$0$0$-672,882$366,145
    Operating Expenses$4.09M$3.55M$2.24M$1.96M$1.01M$1.07M$1.68M$626,606$556,054$798,181$-2,223,804$1.15M
    R&D$310,219$47,061$32,902$15,000$66,675$32,433$62,950$4,098$34,824$2,782$-296,359$86,374
    SG&A$2.16M$1.97M$1.47M$1.12M$604,014$475,499$941,511$341,511$197,047$175,749$-1,599,062$808,576
    Operating Income$-3,706,946$-3,318,643$-1,818,649$-2,198,901$-1,014,401$-1,071,725$-1,677,870$-625,615$-556,054$-798,181$1.55M$-785,551
    Interest Income$146,400$86,072$19,450$30,181$134,727$-437,822$12,646$95$64$86$2,719$25
    Interest Expense$582,241$474,170$50,274$196,880$2$10,474$50,621$641,807$23,597$19,172$64,060$5,713
    Income Before Tax$-2,758,425$-4,461,933$-1,603,733$-2,330,070$-579,490$-1,580,811$-1,718,820$-1,200,862$-552,911$-544,121$1.49M$-779,934
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-2,941,382$-4,967,259$-3,329,035$-2,308,372$-562,355$-1,608,455$-1,934,739$-1,501,257$-1,412,491$-1,397,250$-1,157,916$-783,047
    EBITDA$-2,017,181$-3,899,931$-1,223,030$-2,418,209$-714,194$-1,130,914$-1,677,610$-555,912$-544,089$-503,847$1.48M$-771,334
    EBIT$-2,322,584$-4,073,835$-1,282,787$-2,453,493$-714,215$-1,132,515$-1,680,845$-559,150$-529,378$-525,035$1.47M$-774,246
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ELAB

    News

    Pmgc Holdings Inc., Northstrive Biosciences Inc., Orbit2orbit Pty Ltd and A&B Aerospace, Inc. Enter into Term Sheet for Spaceflight Study and Strategic Relationship

    PMGC Holdings Inc. announced a non-binding term sheet with Orbit2Orbit Pty Ltd. to establish a multi-part strategic relationship. This collaboration focuses on space-based bioscience research, aerospace manufacturing, and a strategic investment by PMGC into the commercial space economy. The agreement outlines plans for NorthStrive Biosciences Inc. to conduct microgravity research using Orbit2Orbit's Mice2Space platform, with A&B Aerospace Inc. providing U.S.-based manufacturing support for the flight hardware.

    www.marketscreener.com•8/25/26•
    Somewhat-Bullish

    PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22 and EL-32, Targeting Microgravity-Induced Muscle Loss

    PMGC Holdings Inc. announced a non-binding term sheet with Orbit2Orbit Pty Ltd to launch a spaceflight study through its subsidiary, NorthStrive Biosciences, targeting microgravity-induced muscle loss with therapeutic candidates EL-22 and EL-32. The multi-part strategic relationship also includes PMGC's A&B Aerospace serving as Orbit2Orbit's preferred U.S. manufacturing partner and a strategic investment by PMGC in Orbit2Orbit. This collaboration aims to expand PMGC's presence in the commercial space economy and leverage its platform model for combined aerospace manufacturing and biotechnology opportunities.

    Yahoo Finance•8/25/26•
    Bullish

    Two muscle-preserving candidates may be tested on mice in space under PMGC's proposal

    PMGC Holdings Inc. announced a non-binding term sheet with Orbit2Orbit Pty Ltd for a three-part strategic relationship, including a "Mice2Space" microgravity research collaboration. This collaboration would involve PMGC's subsidiary NorthStrive Biosciences evaluating its muscle-preserving therapeutic candidates, EL-22 and EL-32, in mice in space to combat microgravity-induced muscle loss. The agreement also includes a U.S. aerospace manufacturing partnership for A&B Aerospace and a strategic equity investment by PMGC in Orbit2Orbit.

    Stock Titan•8/25/26•
    Somewhat-Bullish

    NorthStrive Biosciences Announces The Filing of Two U.S. Patent Applications Targeting Microgravity-Induced Muscle Loss During Long-Duration Spaceflight

    NorthStrive Biosciences, a subsidiary of PMGC Holdings Inc., has filed two U.S. patent applications for its lead assets, EL-22 and EL-32, to address microgravity-induced muscle loss during long-duration spaceflight. These filings aim to position EL-22 and EL-32 as muscle-preservation platforms for both terrestrial markets and the emerging medical needs of human space exploration. The company emphasizes that these preclinical candidates are not yet approved by any regulatory authority and are not currently part of any agreements with space agencies.

    Yahoo Finance Singapore•8/21/26•
    Bullish

    NorthStrive says no drug is approved for spaceflight muscle loss; it files two applications

    NorthStrive Biosciences, a subsidiary of PMGC Holdings (Nasdaq: ELAB), announced the filing of two U.S. patent applications for its preclinical candidates EL-22 and EL-32, aiming to preserve lean muscle mass in humans exposed to microgravity. These filings extend NorthStrive's intellectual property strategy from GLP-1/obesity-related muscle loss and animal health into spaceflight-associated muscle atrophy, leveraging the same myostatin and activin A targeting biology. The company states that no pharmacologic therapy is currently approved for microgravity-induced muscle loss and emphasizes that these candidates are preclinical, not yet evaluated in humans for this specific indication, and there are no existing agreements with space agencies.

    Stock Titan•8/21/26•
    Neutral

    Frequently Asked Questions About ELAB

    Does ELAB pay dividends?
    Elevai Labs, Inc. Common Stock (ELAB) does not currently pay a regular dividend.
    What is ELAB's market cap?
    Elevai Labs, Inc. Common Stock (ELAB) has a market capitalization of $4.30M with a current stock price of $5.19.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In